REGN

Regeneron Pharmaceuticals
D

REGN

635.11
USD
-25.75
(-3.90%)
مفتوح الان
حجم التداول
15,716
الربح لكل سهم
45
العائد الربحي
0.13
P/E
17
حجم السوق
69,411,333,849
أصول ذات صلة
ABBV
ABBV
-9.350
(-4.47%)
200.070 USD
AMGN
AMGN
-9.85
(-3.13%)
304.57 USD
BMY
BMY
-1.580
(-2.59%)
59.460 USD
GILD
GILD
0.330
(0.31%)
106.990 USD
JNJ
JNJ
-2.170
(-1.33%)
160.930 USD
LLY
LLY
-14.75
(-1.71%)
849.26 USD
MRNA
MRNA
-0.410
(-1.20%)
33.770 USD
NVS
NVS
-0.790
(-0.71%)
110.070 USD
PFE
PFE
-0.500
(-1.91%)
25.595 USD
المزيد
الأخبار المقالات

العنوان: Regeneron Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).